Hepatitis C Medicine Trial Shows 100% Cure Rate
Mark Schoenebaum, a biotech analyst with ISI Group, said in a research note that he expects Gilead shares to rise on Monday
hepatitis c medicine trial show cure rate mark schoenebaum biotech analyst isi group say research note expect gilead share rise monday